Developer docs
API playgroundTry for free, no card

Search company profiles

浙江华润三九众益制药有限公司

Full company profile

uuid005navy

Namestring
浙江华润三九众益制药有限公司
Websiteurl
zhypharm.com
Company typeenum
Private
Founded yearstring
-
Descriptiontext

浙江华润三九众益制药有限公司 (Zhejiang China Resources Sanjiu Zhongyi Pharmaceutical Co., Ltd.) is a small China-based pharmaceutical entity headquartered in Lishui, Zhejiang Province. The corporate name indicates an affiliation with China Resources Sanjiu (华润三九), a major state-owned Chinese pharmaceutical group, though the input data does not confirm the parent-subsidiary relationship, ownership stake, or operational linkage. The entity reports a headcount of 13 employees and its listed web address (http://zhypharm.com/) returns a 404 error, indicating that the primary corporate web presence is currently inaccessible or has been removed.

No product portfolio, therapeutic areas, manufacturing capacity, distribution channels, customer segments, or pricing information is present in the available source data. The company profile is empty across technology, products, customers, partnerships, leadership, certifications, funding, and regulatory dimensions. As a result, the entity's specific business function — whether it operates as a manufacturing site, a regional distribution arm, a contract development organization, an R&D shell, or a dormant holding vehicle — cannot be verified from the input. The description is intentionally narrow to avoid inferring scope, scale, or commercial activity beyond what the firmographic record supports.

The fundamental data gap is material: the absence of a functional website, the lack of any disclosed products or customers, a 13-person headcount, and the absence of any external signals (news, funding, regulatory filings, partnerships) collectively imply either a highly localized/non-promotional operating entity, a transitional corporate structure, or a dormant subsidiary. Any downstream investment, M&A, or partnership analysis would require primary-source diligence (corporate registration filings, parent-group disclosures, and direct management inquiry) to confirm operating status, revenue contribution, and strategic role within the broader China Resources Sanjiu group.

Short descriptiontext

浙江华润三九众益制药有限公司 is a small (13-employee) pharmaceutical entity based in Lishui, Zhejiang Province, China, whose name indicates affiliation with the China Resources Sanjiu (华润三九) group. No products, customers, or business model details are disclosed in available sources.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
Markets served

Serves global market

Keyword5 values
pharmaceutical manufacturing, generic drug production, oral solid dosage forms, finished dosage formulations, pharmaceutical tablets
Industry1 code
PRIMARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Generic Pharmaceuticals Manufacturing
No data
Cost components5 values
Personnel, Supply Chain, Operations, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Zhejiang China Resources Sanjiu Zhongyi Pharmaceutical Co., Ltd. (浙江华润三九众益制药有限公司) is a pharmaceutical manufacturer based in Lishui City, Zhejiang Province, China. Operating as a small-scale production entity with approximately 13 employees, the company is positioned as a manufacturing arm within the China Resources Sanjiu (华润三九) pharmaceutical group, focused on finished pharmaceutical dosage production.

Differentiator
Functional benefit
Problem solved
Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers7 records
1China Resources Sanjiu Medical & Pharmaceutical (华润三九)
TypeBroad incumbent
Description

Major Chinese branded pharmaceutical and OTC manufacturer with strong TCM and chemical drug portfolios. Comparable as the apparent parent/affiliated entity and the most relevant reference point for evaluating this subsidiary's strategic role within the CR Sanjiu ecosystem.

2Zhejiang Huahai Pharmaceutical (浙江华海药业)
TypeBroad incumbent
Description

Zhejiang-based generic pharmaceutical manufacturer specializing in finished dosage forms and APIs with strong export focus. Comparable as a Zhejiang-headquartered generic drug manufacturer with similar regulatory and manufacturing profile.

3Yangtze River Pharmaceutical Group (扬子江药业)
TypeBroad incumbent
Description

One of China's largest privately-held pharmaceutical manufacturers focused on generic finished dosage forms across multiple therapeutic areas. Comparable as a Chinese generic FDF manufacturer operating in overlapping categories.

4Harbin Pharmaceutical Group (哈药集团)
TypeBroad incumbent
Description

Large Chinese pharmaceutical group producing branded and generic finished dosage forms including tablets, capsules, and injectables. Comparable as a major Chinese generic drug manufacturer with broad product portfolio.

5Zhejiang Conba Pharmaceutical (浙江康恩贝制药)
TypeRegional player
Description

Zhejiang-based pharmaceutical company producing TCM and chemical drugs in finished dosage forms. Comparable as a regionally-headquartered Chinese pharma manufacturer operating in the same geography.

6Apeloa Pharmaceutical (浙江普洛药业)
TypeRegional player
Description

Zhejiang-based pharmaceutical manufacturer producing APIs and finished dosage forms for domestic and international markets. Comparable as a Zhejiang pharma manufacturer with integrated API-FDF capabilities.

7Livzon Pharmaceutical Group (丽珠医药)
TypeBroad incumbent
Description

Chinese pharmaceutical manufacturer producing chemical drugs, biologics, and TCM products in finished dosage forms. Comparable as a multi-category Chinese pharma manufacturer with generic and specialty products.

Market position
Strengths2 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat1 record

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights3 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

浙江华润三九众益制药有限公司

Generic Pharmaceuticals Manufacturingzhypharm.com

浙江华润三九众益制药有限公司 is a small (13-employee) pharmaceutical entity based in Lishui, Zhejiang Province, China, whose name indicates affiliation with the China Resources Sanjiu (华润三九) group. No products, customers, or business model details are disclosed in available sources.

What 浙江华润三九众益制药有限公司 does

浙江华润三九众益制药有限公司 (Zhejiang China Resources Sanjiu Zhongyi Pharmaceutical Co., Ltd.) is a small China-based pharmaceutical entity headquartered in Lishui, Zhejiang Province. The corporate name indicates an affiliation with China Resources Sanjiu (华润三九), a major state-owned Chinese pharmaceutical group, though the input data does not confirm the parent-subsidiary relationship, ownership stake, or operational linkage. The entity reports a headcount of 13 employees and its listed web address (http://zhypharm.com/) returns a 404 error, indicating that the primary corporate web presence is currently inaccessible or has been removed.

No product portfolio, therapeutic areas, manufacturing capacity, distribution channels, customer segments, or pricing information is present in the available source data. The company profile is empty across technology, products, customers, partnerships, leadership, certifications, funding, and regulatory dimensions. As a result, the entity's specific business function — whether it operates as a manufacturing site, a regional distribution arm, a contract development organization, an R&D shell, or a dormant holding vehicle — cannot be verified from the input. The description is intentionally narrow to avoid inferring scope, scale, or commercial activity beyond what the firmographic record supports.

The fundamental data gap is material: the absence of a functional website, the lack of any disclosed products or customers, a 13-person headcount, and the absence of any external signals (news, funding, regulatory filings, partnerships) collectively imply either a highly localized/non-promotional operating entity, a transitional corporate structure, or a dormant subsidiary. Any downstream investment, M&A, or partnership analysis would require primary-source diligence (corporate registration filings, parent-group disclosures, and direct management inquiry) to confirm operating status, revenue contribution, and strategic role within the broader China Resources Sanjiu group.

浙江华润三九众益制药有限公司 firmographics

Firmographics
Name
浙江华润三九众益制药有限公司
Website
https://zhypharm.com
Company type
Private
Operating status
Operating
Headcount range
11–50 employees
Short description
浙江华润三九众益制药有限公司 is a small (13-employee) pharmaceutical entity based in Lishui, Zhejiang Province, China, whose name indicates affiliation with the China Resources Sanjiu (华润三九) group. No products, customers, or business model details are disclosed in available sources.
Ownership category
akta.pro rank

浙江华润三九众益制药有限公司 industry classification

Industry
Product category
Generic Pharmaceuticals Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing

Keywords

  • Pharmaceutical manufacturing
  • Generic drug production
  • Oral solid dosage forms
  • Finished dosage formulations
  • Pharmaceutical tablets

浙江华润三九众益制药有限公司 business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Operations, Technology or R&D, Infrastructure

浙江华润三九众益制药有限公司 product offering

Product offering

Core offering

Zhejiang China Resources Sanjiu Zhongyi Pharmaceutical Co., Ltd. (浙江华润三九众益制药有限公司) is a pharmaceutical manufacturer based in Lishui City, Zhejiang Province, China. Operating as a small-scale production entity with approximately 13 employees, the company is positioned as a manufacturing arm within the China Resources Sanjiu (华润三九) pharmaceutical group, focused on finished pharmaceutical dosage production.

Differentiator

Problem solved

Functional benefit

Companies that use 浙江华润三九众益制药有限公司

Customer profile

Ideal customer profiles1 record

浙江华润三九众益制药有限公司 technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

浙江华润三九众益制药有限公司 partnerships and signals

Strategic signal

Recent moves1 record

Expansion highlights4 records

浙江华润三九众益制药有限公司 competitors and assessment

Company assessment

Broad incumbents

  • China Resources Sanjiu Medical & Pharmaceutical (华润三九): Major Chinese branded pharmaceutical and OTC manufacturer with strong TCM and chemical drug portfolios. Comparable as the apparent parent/affiliated entity and the most relevant reference point for evaluating this subsidiary's strategic role within the CR Sanjiu ecosystem.
  • Zhejiang Huahai Pharmaceutical (浙江华海药业): Zhejiang-based generic pharmaceutical manufacturer specializing in finished dosage forms and APIs with strong export focus. Comparable as a Zhejiang-headquartered generic drug manufacturer with similar regulatory and manufacturing profile.
  • Yangtze River Pharmaceutical Group (扬子江药业): One of China's largest privately-held pharmaceutical manufacturers focused on generic finished dosage forms across multiple therapeutic areas. Comparable as a Chinese generic FDF manufacturer operating in overlapping categories.
  • Harbin Pharmaceutical Group (哈药集团): Large Chinese pharmaceutical group producing branded and generic finished dosage forms including tablets, capsules, and injectables. Comparable as a major Chinese generic drug manufacturer with broad product portfolio.
  • Livzon Pharmaceutical Group (丽珠医药): Chinese pharmaceutical manufacturer producing chemical drugs, biologics, and TCM products in finished dosage forms. Comparable as a multi-category Chinese pharma manufacturer with generic and specialty products.

Regional players

  • Zhejiang Conba Pharmaceutical (浙江康恩贝制药): Zhejiang-based pharmaceutical company producing TCM and chemical drugs in finished dosage forms. Comparable as a regionally-headquartered Chinese pharma manufacturer operating in the same geography.
  • Apeloa Pharmaceutical (浙江普洛药业): Zhejiang-based pharmaceutical manufacturer producing APIs and finished dosage forms for domestic and international markets. Comparable as a Zhejiang pharma manufacturer with integrated API-FDF capabilities.

Market position

Strengths2 records

Weaknesses3 records

Competitive moat1 record

Key risks4 records

Key highlights3 records

Customer concentration

浙江华润三九众益制药有限公司 financial estimates

Financial estimate

Revenue estimate

Valuation estimate

浙江华润三九众益制药有限公司 leadership team

Management profile

Number of profiles

浙江华润三九众益制药有限公司 funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

浙江华润三九众益制药有限公司 M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 浙江华润三九众益制药有限公司

What does 浙江华润三九众益制药有限公司 do?

Zhejiang China Resources Sanjiu Zhongyi Pharmaceutical Co., Ltd. (浙江华润三九众益制药有限公司) is a pharmaceutical manufacturer based in Lishui City, Zhejiang Province, China. Operating as a small-scale production entity with approximately 13 employees, the company is positioned as a manufacturing arm within the China Resources Sanjiu (华润三九) pharmaceutical group, focused on finished pharmaceutical dosage production.

When was 浙江华润三九众益制药有限公司 founded?

浙江华润三九众益制药有限公司 was founded in -1. It employs 11 to 50 people.

Who are 浙江华润三九众益制药有限公司's main competitors?

Broad incumbents on record are China Resources Sanjiu Medical & Pharmaceutical (华润三九), Zhejiang Huahai Pharmaceutical (浙江华海药业), Yangtze River Pharmaceutical Group (扬子江药业), Harbin Pharmaceutical Group (哈药集团) and Livzon Pharmaceutical Group (丽珠医药). Regional players are Zhejiang Conba Pharmaceutical (浙江康恩贝制药) and Apeloa Pharmaceutical (浙江普洛药业).

Does 浙江华润三九众益制药有限公司 have an API?

No public API is recorded for 浙江华润三九众益制药有限公司.

What industry is 浙江华润三九众益制药有限公司 in?

浙江华润三九众益制药有限公司's product category is Generic Pharmaceuticals Manufacturing. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales